Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.57 |
| ▸ | CSF1R | P07333 | 1/20 | 0.57 |
| ▸ | KIT | P10721 | 1/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 15/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.34 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2053224 | 0.89 | CYP3A4 (0.68) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL3430885 | 0.83 | CYP3A4 (0.71) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL2051936 | 0.82 | CYP3A4 (0.81) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL2050566 | 0.82 | CYP3A4 (0.81) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL3426395 | 0.81 | PDGFRB (0.66) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL2052803 | 0.81 | PDGFRB (0.66) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL3431066 | 0.80 | CYP3A4 (0.71) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL6026886 | 0.80 | CYP3A4 (0.66) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL3429450 | 0.80 | CYP3A4 (0.71) | CYP3A4PDGFRBCSF1RKITPDGFRA | |
| SCHEMBL3431135 | 0.80 | CYP3A4 (0.71) | CYP3A4PDGFRBCSF1RKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | CYP3A4 624/4885PDGFRB 1544/4885CSF1R 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.